BCR-ABL1 Quantitative (p210,p190,p230) Test
Short Name: BCR-ABL1 Quantitative
Also known as: BCR-ABL1 by ddPCR, BCR-ABL1 fusion gene quantification, p210/p190/p230 BCR-ABL1
BCR-ABL1 Quantitative (p210,p190,p230) Test test available at DNA Labs India for ₹9,000. Uses Droplet Digital PCR (ddPCR) on Peripheral Blood samples. Results in Reports are typically available within 2-3 days after sample collection. You will receive a notification when your report is ready.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The primary purpose of the BCR-ABL1 Quantitative test is twofold: 1) To aid in the diagnosis of CML by detecting the presence of the BCR-ABL1 fusion gene, and 2) To monitor the molecular response to treatment in patients already diagnosed with CML. Quantification of BCR-ABL1 transcript levels over time helps determine whether the patient is responding to therapy, achieving major molecular response (MMR), or experiencing resistance or relapse. This information is essential for adjusting treatment plans and making informed clinical decisions.
- Test Code
- 6051
- CPT Code
- 83891
- ICD Code
- C92.1
- Price
- ₹9,000
- Sample Type
- Peripheral Blood
- Result Time
- Reports are typically available within 2-3 days after sample collection. You will receive a notification when your report is ready.
- Fasting Required
- No
- Method
- Droplet Digital PCR (ddPCR)
Sample Collection
No special preparation is required. However, a doctor's prescription is mandatory for this test. Inform your healthcare provider about any medications you are taking, especially tyrosine kinase inhibitors, as they may affect test results.
Method: Venipuncture
Laboratory Analysis
A blood sample will be collected from a vein in your arm by a trained phlebotomist. The procedure is quick and causes minimal discomfort.
Report Delivery
You may resume normal activities immediately after sample collection. There are no restrictions post-test.
Timeline: Reports are typically available within 2-3 days after sample collection. You will receive a notification when your report is ready.
Patient Instructions
About This Test
Who Should Get This Test
The primary purpose of the BCR-ABL1 Quantitative test is twofold: 1) To aid in the diagnosis of CML by detecting the presence of the BCR-ABL1 fusion gene, and 2) To monitor the molecular response to treatment in patients already diagnosed with CML. Quantification of BCR-ABL1 transcript levels over time helps determine whether the patient is responding to therapy, achieving major molecular response (MMR), or experiencing resistance or relapse. This information is essential for adjusting treatment plans and making informed clinical decisions.
How to Prepare
- Sample must be collected in a Streck tube (EDTA) provided by the lab
- Ensure the tube is properly labeled with patient details
- Sample should be transported to the laboratory at ambient temperature (15-25°C) within 24 hours
- Avoid freezing the sample
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"BCR-ABL1 quantification by ddPCR is essential for CML diagnosis and monitoring. Early detection and regular monitoring can significantly improve patient outcomes. This test provides high sensitivity for detecting minimal residual disease."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Clotted or hemolyzed sample
- Incorrect tube type (e.g., heparin tube)
- Sample received after 72 hours of collection
- Inadequate sample volume (< 2 mL)
- Unlabeled or mislabeled sample
Understanding Your Results
BCR-ABL1 not detected
No evidence of BCR-ABL1 fusion gene. This may indicate successful treatment response (deep molecular response) or absence of disease. However, very low levels may be below the detection limit.
BCR-ABL1 ≤ 0.1% IS
Major Molecular Response (MMR) achieved. Indicates good response to TKI therapy. Continue current treatment and monitor regularly.
BCR-ABL1 > 0.1% IS but < 1% IS
Molecular response not optimal. May indicate suboptimal response or emerging resistance. Clinician may consider dose adjustment or alternative therapy.
BCR-ABL1 ≥ 1% IS
Poor molecular response. High levels suggest inadequate response or relapse. Further evaluation and treatment modification are required.
Rising BCR-ABL1 levels over consecutive tests
Indicates loss of response or disease progression. Prompt clinical intervention is necessary.
Consult your oncologist or hematologist if you experience symptoms such as persistent fatigue, unexplained weight loss, night sweats, abdominal fullness, or easy bruising. Also, if you are undergoing CML treatment and your BCR-ABL1 levels are not decreasing as expected, or if you have any concerns about your test results.
Limitations
- ⚠Test detects only the common BCR-ABL1 fusion transcripts (p210, p190, p230); rare breakpoints may not be detected
- ⚠Results should be interpreted in conjunction with clinical findings and other diagnostic tests
- ⚠Quantification is relative to the ABL1 control gene; variations in control gene expression may affect results
- ⚠Not a standalone diagnostic test for CML; bone marrow biopsy may be required for confirmation
- ⚠Test is not intended for screening the general population
Risks & Considerations
- ●Minimal risk of bruising or bleeding at the puncture site
- ●Rare risk of infection or hematoma
- ●Fainting or dizziness during blood draw
Interfering Factors
- ●Sample degradation due to improper storage or transport
- ●Hemolysis or clotting of blood sample
- ●Presence of PCR inhibitors in the sample
- ●Inadequate sample volume
- ●Recent blood transfusion (may dilute leukemic cells)
- ●Concurrent infections or inflammation may affect white blood cell counts
Compare With Similar Tests
| Test | BCR-ABL1 Quantitative (p210,p190,p230) | |||
|---|---|---|---|---|
| Comparison | BCR-ABL1 Quantitative (p210,p190,p230) |
Frequently Asked Questions
What is the BCR-ABL1 Quantitative test?
What is the cost of the BCR-ABL1 Quantitative test at DNA Labs India?
What is the difference between p210, p190, and p230 BCR-ABL1?
Do I need to fast before the test?
How is the sample collected?
How long does it take to get the results?
Is a doctor's prescription required for this test?
What is the significance of BCR-ABL1 quantification in CML treatment?
Can this test detect minimal residual disease (MRD)?
Are there any risks associated with the blood draw?
Is home sample collection available?
What should I do if my BCR-ABL1 levels are high?
Related Tests
B-Cell Rearrangement Detection Test
₹22,000Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel Test
₹20,000Epstein-Barr Virus Early RNA (EBER-ISH) In-Situ-Hybridization Test
₹6,000OncoPro NCCN Lung Cancer Panel with PD-L1 Test
₹140,400Acute Myeloid Leukemia (AML) Cytogenetics Panel Test
₹23,000AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test
₹6,000Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.